sorafenib has been researched along with losartan in 9 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 7,231 | 1,245 | 2,118 |
Protein | Taxonomy | sorafenib (IC50) | losartan (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 9.01 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 3 (33.33) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H | 1 |
Carter, JJ; Fretwell, LV; Woolard, J | 1 |
Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
Abdelgalil, AA; Ahamad, SR; Al-Jenoobi, FI; Mohamed, OY | 1 |
Gillani, TB; Murray, M; Nair, PC; Rawling, T | 1 |
2 review(s) available for sorafenib and losartan
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
7 other study(ies) available for sorafenib and losartan
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib | 2014 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat.
Topics: Animals; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Heart; Heart Rate; Losartan; Male; Metabolomics; Myocardium; Protein Kinase Inhibitors; Rats, Wistar; Sorafenib | 2020 |
Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite.
Topics: Adult; Biotransformation; Catalytic Domain; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Humans; Losartan; Male; Metabolome; Microsomes, Liver; Middle Aged; Molecular Docking Simulation; Oxidation-Reduction; Oxides; Sorafenib; Substrate Specificity | 2021 |